Literature DB >> 78300

Does endotoxin cause both the disease and parasite death in acute malaria and babesiosis?

I A Clark.   

Abstract

When mice are infected with either of several species of Plasmodium or Babesia the amount of Escherichia coli lipopolysaccharide (L.P.S.) required to kill them is decreased several hundred fold. The higher their parasitaemia the greater their susceptibility. There is indirect evidence that more L.P.S. than usual is present during infection with these parasites. In a very susceptible host this may be sufficient to produce endotoxin shock. Non-antibody mediators able to kill rapidly dividing cells, which are released during endotoxin shock, may then control the parasitaemia of acute primary attacks. This may explain why agents such as B.C.G., which produce responsiveness to abnormally low concentrations of L.P.S., protect against infection with certain of these parasities. It may also explain why host species naturally resistance to L.P.S. become ill only at high parasite concentrations, and why others with a naturally high susceptibility to L.P.S. become ill when infected with relatively few parasites. In the individual host convalescence from certain bacterial infections or concomitant infection with L.P.S.-producing organisms may vary the parasitaemia required to produce illness.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 78300     DOI: 10.1016/s0140-6736(78)91386-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  40 in total

1.  Thiolated recombinant human tumor necrosis factor-alpha protects against Plasmodium berghei K173-induced experimental cerebral malaria in mice.

Authors:  N S Postma; R C Hermsen; D J Crommelin; W M Eling; J Zuidema
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Roles of CD4- and CD8-bearing T lymphocytes in the immune response to the erythrocytic stages of Plasmodium chabaudi.

Authors:  G Süss; K Eichmann; E Kury; A Linke; J Langhorne
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

Review 3.  Parasite virulence, co-infections and cytokine balance in malaria.

Authors:  Raquel Müller Gonçalves; Nathália Ferreira Lima; Marcelo Urbano Ferreira
Journal:  Pathog Glob Health       Date:  2014-05-23       Impact factor: 2.894

4.  Plasmodium falciparum merozoite surface protein 1 blocks the proinflammatory protein S100P.

Authors:  Michael Waisberg; Gustavo C Cerqueira; Stephanie B Yager; Ivo M B Francischetti; Jinghua Lu; Nidhi Gera; Prakash Srinivasan; Kazutoyo Miura; Balazs Rada; Jan Lukszo; Kent D Barbian; Thomas L Leto; Stephen F Porcella; David L Narum; Najib El-Sayed; Louis H Miller; Susan K Pierce
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

Review 5.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

6.  Antioxidants can prevent cerebral malaria in Plasmodium berghei-infected mice.

Authors:  C M Thumwood; N H Hunt; W B Cowden; I A Clark
Journal:  Br J Exp Pathol       Date:  1989-06

7.  Tumour necrosis factor-dependent parasite-killing effects during paroxysms in non-immune Plasmodium vivax malaria patients.

Authors:  N D Karunaweera; R Carter; G E Grau; D Kwiatkowski; G Del Giudice; K N Mendis
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

8.  Evidence for reactive oxygen intermediates causing hemolysis and parasite death in malaria.

Authors:  I A Clark; N H Hunt
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

9.  Possible importance of macrophage-derived mediators in acute malaria.

Authors:  I A Clark; J L Virelizier; E A Carswell; P R Wood
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

10.  Demonstration of a lipopolysaccharide-induced cytostatic effect on malarial parasites.

Authors:  C M Rzepczyk; I A Clark
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.